Thursday is also the busiest biotech earnings days of the week, with
(CELG - Get Report)
(GILD - Get Report)
all reporting second-quarter results.
Amgen: Analysts are looking for earnings of $1.54 per share on total revenue of $4.08 billion. Worldwide Aranesp sales are expected to total $525 million in the quarter, Prolia/Xgeva sales $279 million, Enbrel sales $962 million.
Celgene: Consensus earnings of $1.18 per share on total revenue of $1.35 billion, including Revlimid sales of $922 million.
Gilead Sciences: Consensus earnings of 95 cents per share on total revenue of $2.29 billion, encompassing total product sales of $2.2 billion and worldwide HIV franchise sales of $1.88 billion.
Alkermes: Consensus earnings estimate of 16 cents per share on total revenue of $127.5 million.
United Therapeutics: Consensus earnings estimate of $1.13 per share on total revenue of $213.7 million.
Also reporting second-quarter earnings on Thursday:
Friday, July 27
reports second-quarter earnings.
: FDA approval decision for expansion of the Relistor label to include treatment of opioid-induced constipation in patients with chronic, non-cancer pain.
--Written by Adam Feuerstein in Boston.
>To contact the writer of this article, click here:
>To follow the writer on Twitter, go to
>To submit a news tip, send an email to:
and become a fan on